2.11
price down icon6.64%   -0.15
after-market After Hours: 2.11
loading
Inhibikase Therapeutics Inc stock is traded at $2.11, with a volume of 93,404. It is down -6.64% in the last 24 hours and down -10.97% over the past month. Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$2.26
Open:
$2.22
24h Volume:
93,404
Relative Volume:
0.56
Market Cap:
$140.51M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.6741
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
+11.05%
1M Performance:
-10.97%
6M Performance:
-12.81%
1Y Performance:
+11.05%
1-Day Range:
Value
$2.095
$2.23
1-Week Range:
Value
$1.785
$2.26
52-Week Range:
Value
$1.12
$4.20

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name
Name
Inhibikase Therapeutics Inc
Name
Phone
678-392-3419
Name
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Name
Employee
16
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
IKT's Discussions on Twitter

Compare IKT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IKT
Inhibikase Therapeutics Inc
2.11 140.51M 0 -19.57M -17.24M -3.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-12-25 Downgrade H.C. Wainwright Buy → Neutral

Inhibikase Therapeutics Inc Stock (IKT) Latest News

pulisher
Apr 15, 2025

In wake of Anthos buyout, CFO McIntyre joins Inhibikase - BioCentury

Apr 15, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics appoints new CFO - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan

Apr 14, 2025
pulisher
Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 04, 2025

In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st

Apr 04, 2025
pulisher
Apr 04, 2025

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo

Apr 04, 2025
pulisher
Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times

Mar 28, 2025
pulisher
Mar 27, 2025

Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan

Mar 27, 2025
pulisher
Mar 23, 2025

INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 21, 2025

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 05, 2025

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research

Mar 05, 2025
pulisher
Feb 25, 2025

After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury

Feb 25, 2025
pulisher
Feb 24, 2025

Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase enhances leadership with new appointments - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World

Feb 24, 2025
pulisher
Feb 18, 2025

Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan

Feb 18, 2025
pulisher
Feb 17, 2025

What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World

Feb 15, 2025
pulisher
Feb 12, 2025

HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 01, 2025

Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter

Jan 31, 2025
pulisher
Jan 31, 2025

Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St

Jan 31, 2025
pulisher
Jan 30, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 30, 2025
pulisher
Jan 30, 2025

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn

Jan 30, 2025
pulisher
Jan 30, 2025

Inhibikase shelves Parkinson’s asset after Phase 2 flop - Endpoints News

Jan 30, 2025
pulisher
Jan 28, 2025

Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World

Jan 28, 2025

Inhibikase Therapeutics Inc Stock (IKT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):